A. T. Tuğlular Et Al. , "Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey," 19th International Myeloma Society Annual Meeting , California, United States Of America, pp.190-191, 2022
Tuğlular, A. T. Et Al. 2022. Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey. 19th International Myeloma Society Annual Meeting , (California, United States Of America), 190-191.
Tuğlular, A. T., Pehlivan, M., Sönmez, M., Hacıoğlu, S., Saydam, G., Ayyıldız, M. O., ... Kaynar, L.(2022). Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey . 19th International Myeloma Society Annual Meeting (pp.190-191). California, United States Of America
Tuğlular, Ayşe Et Al. "Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey," 19th International Myeloma Society Annual Meeting, California, United States Of America, 2022
Tuğlular, Ayşe T. Et Al. "Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey." 19th International Myeloma Society Annual Meeting , California, United States Of America, pp.190-191, 2022
Tuğlular, A. T. Et Al. (2022) . "Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey." 19th International Myeloma Society Annual Meeting , California, United States Of America, pp.190-191.
@conferencepaper{conferencepaper, author={Ayşe Tülin Tuğlular Et Al. }, title={Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey}, congress name={19th International Myeloma Society Annual Meeting}, city={California}, country={United States Of America}, year={2022}, pages={190-191} }